Press release
Investigation announced for Long-Term Investors in shares of ImmunityBio, Inc. (NASDAQ: IBRX)
An investigation on behalf of current long term investors in ImmunityBio, Inc. (NASDAQ: IBRX) shares over possible breaches of fid
Investors who are current long term investors in ImmunityBio, Inc. (NASDAQ: IBRX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors NASDAQ: IBRX stocks follows a lawsuit filed against ImmunityBio, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: IBRX stocks, concerns whether certain ImmunityBio, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Southern District of California the plaintiff alleges that, the Defendants made false and/or misleading statements and/or failed to disclose that ImmunityBio conducted insufficient due diligence to discover, or else did discover and ignored, GMP deficiencies at its third-party CMOs for Anktiva, that one or more of the Company's third-party CMOs for Anktiva did in fact suffer from GMP deficiencies, that the foregoing deficiencies was likely to cause the FDA to reject the Anktiva BLA in its present form, that accordingly, the Company overstated the regulatory approval prospects for the Anktiva BLA, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of ImmunityBio, Inc. (NASDAQ: IBRX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of ImmunityBio, Inc. (NASDAQ: IBRX) here
News-ID: 3265608 • Views: …
More Releases from Shareholders Foundation
Lawsuit filed for certain Investors who lost money with shares of Global Cord Bl …
An investor, who purchased shares of Global Cord Blood Corporation (OTC: CORBF), filed a lawsuit over alleged violations of Federal Securities Laws by Global Cord Blood Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Global Cord Blood Corporation (OTC: CORBF) have certain options and for certain investors are short and strict deadlines running. Deadline: June 24, 2024. OTC: CORBF investors should contact the Shareholders…
Lawsuit filed for Investors who lost money with shares of Autodesk, Inc. (NASDAQ …
An investor, who purchased shares of Autodesk, Inc. (NASDAQ: ADSK), filed a lawsuit over alleged violations of Federal Securities Laws by Autodesk, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Autodesk, Inc. (NASDAQ: ADSK) have certain options and for certain investors are short and strict deadlines running. Deadline: June 24, 2024. NASDAQ: ADSK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Investors who lost money with shares of AST SpaceMobile, Inc. (NASDAQ: ASTS) sho …
An investor, who purchased shares of AST SpaceMobile, Inc. (NASDAQ: ASTS), filed a lawsuit over alleged violations of Federal Securities Laws by AST SpaceMobile, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of AST SpaceMobile, Inc. (NASDAQ: ASTS) have certain options and for certain investors are short and strict deadlines running. Deadline: June 17, 2024. NASDAQ: ASTS investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors who lost money with shares of Sharecare, Inc. (NASDA …
An investor, who purchased shares of Sharecare, Inc. (NASDAQ: SHCR), filed a lawsuit over alleged violations of Federal Securities Laws by Sharecare, Inc.
Investors who purchased shares of Sharecare, Inc. (NASDAQ: SHCR) have certain options and for certain investors are short and strict deadlines running. Deadline: June 18, 2024. NASDAQ: SHCR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Atlanta, GA based Sharecare, Inc. operates as…
More Releases for ImmunityBio
Acute Myeloid Leukemia Therapeutic Pipeline Analysis | Insights into the Latest …
As per DelveInsight's assessment, globally, nearly 260+ key pharma and biotech companies are working on 260+ pipeline drugs in the Acute Myeloid Leukemia therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Acute Myeloid Leukemia Pipeline Insight, 2022" report by DelveInsight provides a…
Anti-neoplastic Therapy Market is expected to be valued at USD 134 Billion in 20 …
According to Precision Business Insights (PBI), the latest report, the market value of the anti-neoplastic therapy market is expected to be valued at USD 134 billion in 2022, which is expected to grow at a CAGR of 7.8% from 2022-2028. The primary factors that drive the market are the increasing demand for personalized medicines, the growing prevalence of cancer, an increase in research and development activities in biotechnology and pharmaceutical…
Pancreatic Cancer Market to Progress at a CAGR of 7.3 % by 2032 | DelveInsight
DelveInsight's Pancreatic Cancer Market Insights report includes a comprehensive understanding of current treatment practices, pancreatic cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.
The pancreatic cancer market is anticipated to show positive growth, mainly attributed to the increasing incident cases and also, the…
Natural Killer (NK) Cell Therapeutics Market Size, Future Forecasts, Growth Rate …
A new market study is released on Global "Natural Killer (NK) Cell Therapeutics Market 2022" with data Tables for historical and forecast years represented with Chats & Graphs with easy to understand detailed analysis. The report also sheds light on present scenario and upcoming trends and developments that are contributing in the growth of the market. In addition, key market boomers and opportunities driving the market growth are provided that…
Colorectal Cancer Pipeline Assessment | In-depth Analysis into the Clinical Tria …
As per DelveInsight's assessment, globally, nearly 150+ key pharma and biotech companies are working on 150+ pipeline drugs in the Colorectal Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA) and molecule types. Several of the therapies are in the advanced stages of clinical development expected to launch in the coming years.
"Colorectal Cancer Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of…
Non-muscle Invasive Bladder Cancer Market is Estimated to Showcase a Significant …
DelveInsight's "Non-muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-muscle Invasive Bladder Cancer Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Non-muscle Invasive Bladder Cancer market report covers emerging drugs, treatment practices, market share of the individual therapies,…
